Drugs · acquisition-cost intelligence
buprenorphine transdermal system
buprenorphine· ingredient buprenorphineDrugs used in opioid dependence· BUPRENORPHINE 10 ug/h; BUPRENORPHINE 15 ug/h; BUPRENORPHINE 20 ug/h; BUPRENORPHINE 5 ug/h
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$44.86
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other buprenorphine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Buprenorphine | $0.41449 | −$44.45 |
| Buprenorphine and Naloxone | $0.55472 | −$44.31 |
| Buprenorphine and Naloxone Sublingual Film | $2.26 | −$42.60 |
| Buprenorphine and Naloxone | $3.25 | −$41.61 |
Medicare Part D coverage · CY2026
On 227 plan formularies · typical tier 4
Prior auth 35% · Step therapy 0% · Quantity limit 98% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.